Table 1.

Patient characteristics

CHD3CSDHSDHN
Demographics
    male gender (%)42507580
    age (years)52 ± 1455 ± 1647 ± 1557 ± 10
    vintage (years)4.7 ± 3.95.6 ± 5.25.4 ± 6.810.7 ± 9.6
    diabetes (%)58581710
    IHD (%)833820
    mean resting ejection fraction (%)30–4030–4030–4030–40
Plasma measures
    pre-HD Na+ (mmol/L)136 ± 3136 ± 4138 ± 2137 ± 5
    post-HD Na+ (mmol/L)140 ± 3140 ± 5137 ± 2137 ± 2
    pre-HD K+(mmol/L)5.1 ± 0.65.2 ± 0.84.4 ± 0.54.2 ± 0.5
    post-HD K+(mmol/L)3.4 ± 0.54.2 ± 0.73.4 ± 0.43.3 ± 0.4
    pre-HD BUN (mmol/L)23.2 ± 5.218.1 ± 3.823.3 ± 7.120.3 ± 10.6
    post-HD BUN (mmol/L)6.6 ± 1.98.8 ± 2.013.6 ± 4.211.4 ± 7.3
    pre-HD Creat (μmol/L)888 ± 241619 ± 195936 ± 276738 ± 212
    post-HD Creat (μmol/L)330 ± 95298 ± 126535 ± 165421 ± 165
    pre-HD Ca2+ (mmol/L)2.25 ± 0.202.3 ± 0.132.31 ± 0.192.25 ± 0.17
    post-HD Ca2+ (mmol/L)2.34 ± 0.132.32 ± 0.162.39 ± 0.162.36 ± 0.09
    pre-HD Phos (mmol/L)1.9 ± 0.71.7 ± 0.11.7 ± 0.51.5 ± 0.7
    post-HD Phos (mol/L)0.8 ± 0.30.9 ± 0.20.8 ± 0.20.8 ± 0.3
Medications
    ESA (%)9292100100
    beta-blockers (%)25880
    ACE inhibitors (%)0880
    calcium channel blockers (%)331780
    diuretics (%)0000
    other AHTs (%)00010
    iron (%)67337560
  • The data are presented as the means ± SD, unless otherwise indicated. ESA, erythropoietin–stimulating agent (darbepoetin or erythropoietin); AHT, antihypertensive medication; ACE, angiotensin-converting enzyme; HD, hemodialysis; CHD3, conventional thrice-weekly in-center hemodialysis; CSD, short-daily hemodialysis; HSD, at home hemodialysis; HN, home nocturnal hemodialysis; IHD, ischemic heart disease; Creat, creatinine; BUN, blood urea nitrogen; phos, phosphate.